These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 36925714)

  • 1. Micro and nanotechnologies: The little formulations that could.
    Stiepel RT; Duggan E; Batty CJ; Ainslie KM
    Bioeng Transl Med; 2023 Mar; 8(2):e10421. PubMed ID: 36925714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.
    Patel R; Kaki M; Potluri VS; Kahar P; Khanna D
    Hum Vaccin Immunother; 2022 Dec; 18(1):2002083. PubMed ID: 35130825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccine Evolution and Beyond.
    Brice Y; Morgan L; Kirmani M; Kirmani M; Udeh MC
    Neurosci Insights; 2023; 18():26331055231180543. PubMed ID: 37351483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotechnology, nanotechnology and medicine.
    Contera S; Bernardino de la Serna J; Tetley TD
    Emerg Top Life Sci; 2020 Dec; 4(6):551-554. PubMed ID: 33295610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Trends in Micro- and Nanoscale Technologies in Medicine: From Basic Discoveries to Translation.
    Alvarez MM; Aizenberg J; Analoui M; Andrews AM; Bisker G; Boyden ES; Kamm RD; Karp JM; Mooney DJ; Oklu R; Peer D; Stolzoff M; Strano MS; Trujillo-de Santiago G; Webster TJ; Weiss PS; Khademhosseini A
    ACS Nano; 2017 Jun; 11(6):5195-5214. PubMed ID: 28524668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview.
    Shiravi AA; Ardekani A; Sheikhbahaei E; Heshmat-Ghahdarijani K
    Cardiol Ther; 2022 Mar; 11(1):13-21. PubMed ID: 34845662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic?
    Uskoković V
    Nanomedicine (Lond); 2020 Jul; 15(17):1719-1734. PubMed ID: 32462968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracking the COVID-19 vaccines: The global landscape.
    Yadav T; Kumar S; Mishra G; Saxena SK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2191577. PubMed ID: 36995773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
    Nguyen S; Bastien E; Chretien B; Sassier M; Defer G; Nehme A; Lelong-Boulouard V; Alexandre J; Fedrizzi S; Morice PM
    Ann Neurol; 2022 Dec; 92(6):1080-1089. PubMed ID: 36054163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.
    Noor R
    Curr Clin Microbiol Rep; 2021; 8(3):178-185. PubMed ID: 33686365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate and adaptive immune responses toward nanomedicines.
    Viana IMO; Roussel S; Defrêne J; Lima EM; Barabé F; Bertrand N
    Acta Pharm Sin B; 2021 Apr; 11(4):852-870. PubMed ID: 33747756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
    Wang C; Zhang Y; Dong Y
    Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.